Project Grant R01CA286651

Award Date 7/1/24

Completion Date 6/30/29

Dollars Obligated $1.4M

Federal Agency

National Cancer Institute

Awardee

Cold Spring Harbor Laboratory (GV31TMFLPY88)

Federal Grant Program

93.396

Assistance Type

Project Grant

Place of Performance

Cold Spring Harbor, NY 11724, USA

Similar Awards

Project Grant R01CA295898
Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of California, San Diego a $534,083 Project Grant effective June 3, 2025, under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on glucocorticoid signaling mechanisms induced by breast cancer cell-derived extracellular vesicles. The research project, scheduled for completion by May 31, 2030, will investigate how extracellular vesicles produced by breast cancer cells trigger...
Project Grant R35CA305347
Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $1.056 million to the Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) to support research on overcoming resistance to targeted therapies in breast cancer. Initiated August 20, 2025, and extending through July 31, 2032, this project delivers fundamental and applied research aimed at understanding and addressing the development of drug resistance in...
Project Grant R21CA302986
Federal Project Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a $416,818 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for the period August 1, 2025 through July 31, 2027. The award supports preclinical research investigating whether physical activity enhances Chimeric Antigen Receptor (CAR)-T cell immunotherapy effectiveness in metastatic breast cancer by normalizing the tumor microenvironment. The research will employ...
Project Grant HT94252510078
The federal Project Grant award titled "TARGETING HYPOTHALAMIC NEURONS TO ABROGATE STRESS-INDUCED BREAST CANCER GROWTH" was awarded to Cold Spring Harbor Laboratory (CSHL) by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,440,000 award, effective from March 1, 2025 through February 29, 2028, will support advanced biomedical research at CSHL aimed at investigating the role of hypothalamic neurons in stress-induced breast...
Project Grant F32CA298459
Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $151,040 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective January 16, 2026, with completion targeted for July 31, 2028. This award supports a research training and development initiative focused on investigating the role of interferon gamma (IFNγ) in promoting metastasis and immune evasion in triple negative breast cancer (TNBC). The project comprises two primary...
Project Grant R01DK146265
Project Grant Award Summary Brigham & Women's Hospital Inc., operating under its Department of Faulkner Pathology, received a $894,808 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award, effective April 1, 2026, through March 31, 2031, supports a five-year research initiative investigating sex differences in the adverse metabolic effects of...
Project Grant R03CA300614
Federal Grant Award Summary The National Cancer Institute awarded $178,000 to the Beckman Research Institute of the City of Hope under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for a Project Grant commencing June 23, 2025, with a completion date of May 31, 2027. The research focuses on evaluating the ELF5 (E74-like factor 5) clock as a novel biomarker for breast cancer prevention clinical trials. The ELF5 clock is a breast-specific biological aging measurement tool that...
Project Grant K99CA293266
Federal Grant Award Summary The National Cancer Institute awarded Brigham & Women's Hospital Inc. a Project Grant of $155,605 under the Cancer Research Manpower program (CFDA 93.398) effective September 12, 2025, with completion scheduled for August 31, 2026. This award supports research designed to elucidate the mechanisms underlying the association between oral contraception use and ovarian and breast cancer risk through comprehensive metabolomic profiling. The principal investigator...
Project Grant HT94252310983
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $920,228 project grant to the University of Colorado-Denver on September 15, 2023. The grant, titled "ANDROGEN RECEPTORS IN LUMINAL BREAST CANCER: EFFECTS ON RESPONSE TO ENDOCRINE THERAPY AND AN IMMUNE-SUPPRESSIVE TUMOR IMMUNE MICROENVIRONMENT (TIME)", will fund research to investigate the role of androgen receptors in luminal breast cancer and their impact on response to endocrine...
Project Grant R01CA296071
Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of Miami a $2.75 million Project Grant on September 12, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a four-year randomized controlled trial examining the effects of remotely-delivered cognitive behavioral stress management (R-CBSM) on cancer-accelerated aging in older breast cancer survivors. The study will enroll 192 distressed, post-menopausal breast cancer survivors...

CENTRAL MECHANISMS OF GLUCOCORTICOID CIRCADIAN RHYTHM DYSFUNCTION IN BREAST CANCER - PROJECT SUMMARY BREAST CANCER IS STILL THE MOST COMMON MALIGNANCY IN WOMEN WORLDWIDE. DESPITE THE INCREDIBLE ADVANCES MADE IN THE PAST DECADES TOWARDS ELIMINATING BREAST CANCER, NEARLY ALL WOMEN WITH METASTATIC BREAST CANCER WILL SUCCUMB TO THE DISEASE. THEREFORE, WE DESPERATELY NEED NEW AND IMPROVED APPROACHES TOWARDS ELIMINATING BREAST CANCER. THE PROPOSED WORK FOCUSES ON A WIDELY DOCUMENTED CLINICAL FINDING WITH NO KNOWN UNDERLYING MECHANISM: BLUNTED CIRCULATING GLUCOCORTICOID RHYTHMS IN PATIENTS WITH BREAST CANCER. CRITICALLY, PATIENTS WITH 'FLAT' OR 'BLUNTED' CIRCADIAN RHYTHMS IN CIRCULATING GLUCOCORTICOIDS (E.G., CORTISOL) REPORT LOWER QUALITY OF LIFE AND DIE FROM CANCER EARLIER THAN PATIENTS WITH NORMAL 'ROBUST' CIRCADIAN RHYTHMS. GLUCOCORTICOID RHYTHMS ARE LARGELY CONTROLLED BY CONCERTED INTERACTIONS AMONG THE HYPOTHALAMUS, PITUITARY, AND ADRENAL GLANDS (I.E., HPA-AXIS), AND ACT TO REGULATE DIVERSE PHYSIOLOGICAL PROCESSES ESSENTIAL FOR HEALTH INCLUDING IMMUNE CELL TRAFFICKING/POLARIZATION, ENERGY MOBILIZATION, AROUSAL, AND SYNCHRONIZATION OF PERIPHERAL CIRCADIAN CLOCKS. OUR PRELIMINARY DATA DEMONSTRATE THAT PRECLINICAL MOUSE MODELS OF BREAST CANCER ALSO EXHIBIT THIS 'BLUNTING' OF THE GLUCOCORTICOID RHYTHM, AND THIS IS ACCOMPANIED BY ABERRANT ACTIVITY WITHIN HYPOTHALAMIC NEURONS THAT REGULATE THE HPA-AXIS (I.E., PVNCRH NEURONS). ADDITIONALLY, BY RE-ESTABLISHING A ROBUST GLUCOCORTICOID RHYTHM VIA CHEMOGENETIC STIMULATION OF THESE NEURONS, WE WERE ABLE TO SIGNIFICANTLY IMPEDE PRIMARY BREAST CANCER GROWTH IN MOUSE MODELS. IN THE PRESENT PROPOSAL, WE WILL SYSTEMATICALLY DETERMINE WHERE ALONG HPA-AXIS DYSFUNCTION OCCURS IN RESPONSE TO BREAST CANCER, IDENTIFY THE MECHANISM(S) DRIVING THIS DYSFUNCTION, AND THEN USE ORTHOGONAL APPROACHES TO MANIPULATE THESE MECHANISMS TO CONFER BENEFITS (REDUCED TUMOR AND METASTATIC BURDEN, ENHANCED RESPONSES TO CHECKPOINT BLOCKADE IMMUNOTHERAPY) IN MOUSE MODELS OF BREAST CANCER. THESE STUDIES REPRESENT A SIGNIFICANT STEP FORWARD IN OUR UNDERSTANDING OF HOW MALIGNANT PROCESSES INFLUENCE THE HOST, AND HOW HOST RESPONSES DICTATE CANCER PROGRESSION AND THERAPEUTIC EFFICACY. THESE DATA WILL FURTHER INFORM THE DESIGN OF NOVEL THERAPEUTIC APPROACHES TOWARDS ELIMINATING BREAST CANCER BY TARGETING THE HPA-AXIS.

Posted 6/27/24

Mod #	Federal Obligation	Date
Not listed	$460.8k	6/3/25
Not listed	$456.0k	6/27/24
Not listed	$456.0k	6/27/24